The cardiac interventional suite – where catheter-based procedures are employed to treat everything from heart attacks to atrial fibrillation – has historically been a setting where high-tech, cutting-edge diagnostic and therapeutic tools are often welcomed and, in many cases, even conceived and fostered. However, in the current economic climate, with hospitals scrutinizing their expenditures more closely than ever before, such tools must now prove themselves above and beyond what was required in the past. Hospital purchasing departments have clearly raised the bar for new technologies – and many hospitals now require some type of proven, value-added benefit before agreeing to make the purchase. Such qualifications are typically defined as a direct reduction in procedural costs, an improvement in patient safety or outcomes, an added value in terms of reimbursement, or an increase in operating efficiency.
The situation is compounded by the fact that interventionalists are losing some of the clout they once enjoyed that enabled them to readily dictate the purchase of physician-preference items. This...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
